Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients.

ABSTRACT:

Introduction

The aim of this study was to determine the efficacy of early tocilizumab treatment for hospitalized patients with COVID-19 disease.

Methods

Open-label randomized phase II clinical trial investigating tocilizumab in patients with proven COVID-19 admitted to the general ward and in need of supplemental oxygen. The primary endpoint of the study was 30-day mortality with a prespecified 2-sided significance level of α = 0.10. A post-hoc analysis was performed for a combined endpoint of mechanical ventilation or death at 30 days. Secondary objectives included comparing the duration of hospital stay, ICU admittance and duration of ICU stay and the duration of mechanical ventilation.

Results

A total of 354 patients (67% men; median age 66 years) were enrolled of

SUBMITTER: Rutgers A 

PROVIDER: S-EPMC9374226 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature